Sintana advances Challenger deal, updates Orange Basin exploration plans

Geomega Resources (TSX-V:GMA) CEO Kiril Mugerman talked with Proactive's Stephen Gunnion about the company’s bauxite residue technology and its potential global impact. In the interview, Mugerman explained how Geomega is addressing the 200 million tonnes of bauxite residue generated annually, with over 4.5 billion tonnes currently stored globally. He detailed the company's clean technology solution designed to convert this industrial waste into value. "This is a technology for bauxite residues," Mugerman said, describing how the waste, which results from aluminum refining, can be treated instead of being left to accumulate in storage ponds. Mugerman highlighted Geomega’s joint development agreement with Rio Tinto, valued at C$4.5 million, to build a demonstration plant in Saguenay, Quebec. Although the timeline is controlled by Rio Tinto, the goal is to complete the project within approximately two years. The CEO also spoke about presenting bench-scale results in China, which demonstrated over 90% residue volume reduction and successful performance across six different bauxite residue sources. The next step is to scale to a demonstration plant. “A major company gave the green light to do the next scale up, which is exciting,” he noted. Mugerman also emphasized the role of government support in advancing the technology readiness level, helping position Geomega for future commercial agreements. For more interviews, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future updates. #GeomegaResources #BauxiteResidue #CleanTech #RioTinto #AluminiumRecycling #WasteToValue #CriticalMinerals #SustainableMining #GreenTechnology #CanadaMining

Sintana Energy CEO Robert Bose joined Steve Darling from Proactive to discuss the company’s progress on two major fronts: the advancement of its acquisition of Challenger and new developments across key blocks in Namibia’s Orange Basin. Bose reported that the planned acquisition of Challenger has now satisfied several significant conditions, including formal consent from ANCAP—Uruguay’s national hydrocarbon regulator—and confirmation from Chevron indicating no objection to the transaction. With these milestones achieved, the deal now only requires final approval from the TSX Venture Exchange. A Court Sanction Hearing, originally delayed following later-than-expected ANCAP approval, has been rescheduled for December 12. On 26 November 2025, Challenger confirmed that the Scheme of Arrangement received strong shareholder backing, with the requisite majorities approving both the Scheme at the Court Meeting and the related Special Resolution at the General Meeting. Pending court sanction, registration of the Court Order, and satisfaction or waiver of remaining conditions outlined in the Scheme Document, the transaction is expected to become effective on 16 December 2025. Bose also provided an important operational update on Blocks 2813A and 2814B in Namibia’s Orange Basin—one of the world’s most closely watched offshore exploration regions. The blocks fall under Petroleum Exploration License 83 (PEL 83), currently operated by a subsidiary of Galp. Sintana maintains an indirect 49% interest in Custos Energy, which itself holds a 10% working interest in PEL 83, giving Sintana an effective 4.9% carried interest. NAMCOR, Namibia’s state energy company, holds an additional 10% working interest. Major structural changes are underway at the asset level. TotalEnergies and Galp have agreed to a transaction that will see TotalEnergies assume operatorship of PEL 83 and secure a 40% participating interest from Galp, which presently owns 80%. As part of the agreement, the parties will initiate a multi-well exploration and appraisal campaign over the next two years, targeting at least three wells aimed at further de-risking the block and defining a potential first development hub within the acreage. The first exploration well under this new program is currently being assessed for potential drilling in 2026—positioning PEL 83 as a key contributor to the growing momentum in the Orange Basin and reinforcing Sintana’s strategic exposure to one of the most prolific emerging petroleum regions globally. #proactiveinvestors #sintanaenergyinc #tsxv #sei #otcqb #seusf #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #OilExploration #Namibia #OrangeBasin #EnergySector #PEL83 #RobertBose #GalpEnergia #Chevron #QatarEnergy #EnergyNews #ProactiveInvestors #2025EnergyTrends

Aftermath Silver CEO Ralph Rushton joined Steve Darling from Proactive to announce the commencement of a new, targeted follow-up drilling campaign at the company’s flagship Berenguela silver-copper-manganese project in southern Peru. The program includes approximately 4,000 metres of diamond core drilling and 2,000 metres of reverse circulation (RC) drilling, marking a significant new phase of exploration aimed at further enhancing the project’s resource potential. Rushton explained that drilling is also set to begin this week at Aftermath Silver’s Challacollo silver-gold project in Region I of northern Chile. At Challacollo, the company plans to complete between 1,000 and 2,000 metres of core drilling as it advances its exploration strategy across multiple high-priority assets. The decision to accelerate drilling activity reflects both favourable market conditions and strong technical confidence in the projects. Rushton noted that with silver prices currently at elevated levels, the company believes now is the optimal time to advance both exploration and resource growth. At Berenguela, the focus of the program will be on following up high copper grades previously encountered on the eastern side of the existing resource. In addition, infill drilling will target areas believed to represent the most likely location for initial future mining operations. Rushton emphasized that the campaign is designed not only to expand and upgrade known mineralization but also to support longer-term development planning by improving geological confidence in critical zones of the deposit. With two active drill programs underway in Peru and Chile, Aftermath Silver is positioning itself to capitalize on strong metals markets while advancing its portfolio of advanced-stage silver projects. #proactiveinvestors #aftermathsilverltd #tsxv #aag #otcqx #aagff #mining #SilverMining, #BerenguelaProject, #Mining #Silver #Copper #Manganese #Peru #DrillingResults #BatteryMetals #ResourceModel #Investing

Delta Gold Technologies PLC (AQSE:DGQ) CEO Michael Jones joined Stephen Gunnion in the Proactive studio to discuss more about the company’s innovative approach to quantum computing, underpinned by its nanoscale gold-based technology. Jones explained that while many firms claim to have quantum computers, the core challenge of creating stable and scalable qubits remains unresolved. Delta Gold is focused on a novel method using nanoscale gold to address this challenge, backed by a leading research partnership with the University of Toronto. “The power of the quantum computer is something that can cross a whole bunch of different sectors, and that gives us a lot of opportunity to look for partners or licensees to our technology,” Jones said. He highlighted the company’s relationship with Professor Harry Ruda, a globally cited expert who leads Delta Gold’s research efforts, and noted the significant advantage of working within a university ecosystem. Delta Gold has recently listed on the Aquis Stock Exchange, with a market cap now exceeding £10 million following a 50% rise post-IPO. Capital raised will fund a three-year research programme, with IP development and patent filings planned. Jones confirmed that major stockholders are locked in, reflecting strong confidence in the company’s long-term potential. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications to stay updated. #QuantumComputing #DeltaGoldTechnologies #MichaelJones #Qubits #UniversityOfToronto #QuantumResearch #AquisStockExchange #TechInvestment #QuantumIP #EarlyStageTech #GoldInQuantum

Ilika PLC (AIM:IKA, OTCQX:ILIKF) CEO Graeme Purdy talked with Proactive's Stephen Gunnion about a significant milestone for the company as it successfully shipped its 10Ah Goliath battery prototypes on schedule. Purdy noted that the delivery reflects the company's commitment to meeting expectations and keeping to its timelines. The prototypes will now be evaluated by customers, with Ilika expecting collaborative feedback to further refine its solid-state battery technology. Purdy explained that the next key milestone is the development of a 50Ah cell and that licensing discussions are already underway. He emphasised Ilika’s asset-light model, saying that the company does not intend to build large factories itself but will rely on technology transfer and partners to scale up. Ilika’s pilot line has achieved a 93% yield, which Purdy described as a “really great validation that we have a robust process that is ready for scale up.” This result exceeds typical expectations at this stage and supports the transition towards commercialisation. The interview also touched on Ilika’s modelling work with Balance Batteries Ltd, which demonstrated potential cost and performance benefits for EV applications. The company claims a 20% reduction in battery pack costs and a corresponding increase in vehicle range when using its technology. To conclude, Purdy shared that further updates may follow from Ilika’s Stereax product line as the year closes, with half-year results expected in early 2026. For more interviews and insights, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications to stay up to date. #IlikaPLC #SolidStateBatteries #EVTechnology #BatteryInnovation #CleanEnergy #GoliathBattery #Stereax #TechTransfer #BatteryPrototypes #PilotLine #EnergyStorage #ProactiveInvestors

Fineqia International Inc (CSE:FNQ) senior associate Matteo Greco talked with Proactive's Stephen Gunnion about the key takeaways from the firm’s November report on crypto exchange-traded products (ETPs), which tracked a 17% drop in crypto assets – closely aligned with a broader 16% market decline. Despite the downturn, Greco noted that outflows from ETPs were minimal, indicating growing maturity and long-term investor confidence in crypto-backed financial products. “This is a strong vehicle to get exposure to the asset class,” Greco said, emphasizing the resilience of the crypto ETP market. He highlighted that Bitcoin ETPs saw only $3 billion in outflows despite a 17.5% price drop, suggesting that investors in these products tend to have a longer investment horizon. Similarly, while Ethereum ETPs recorded their first monthly outflows after seven months of inflows, Greco said that, proportional to market cap, Ethereum has attracted relatively stronger demand than Bitcoin. Regarding altcoin ETPs, Greco pointed to a positive trend driven by recent US ETF approvals for assets like Solana and Dogecoin. He added that the broader range of products could signal the early signs of an "alt season." Looking ahead, Greco believes the launch of over 300 listed crypto ETPs indicates sustained institutional interest heading into 2026. For more expert insights like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #CryptoETPs #Fineqia #BitcoinETP #EthereumETP #Altcoins #CryptoInvesting #ETFs #InstitutionalCrypto #CryptoMarkets #ProactiveInvestors

Optima Health PLC (AIM:OPT) chief executive Jonathan Thomas talked with Proactive's Stephen Gunnion about the company’s strong first half performance, posting 17% revenue growth. Thomas credited both organic expansion and recent M&A activity, including the acquisitions of Cognate Health in Ireland and Care first, as key contributors. “The market backdrop is really good. There's great demand for our services. We're winning new business, and we anticipate to continue to grow,” said Thomas. He outlined how Cognate Health has now been rebranded as Optima Health Ireland, with the company beginning to leverage revenue synergies across jurisdictions. Care first, which complements Optima’s existing EAP and mental health operations, is expected to complete its integration in Q4 of the current financial year. Thomas also discussed the company’s operational transformation programme, which is designed to improve margins and scale effectively as growth continues. This includes clinical enhancements, automating processes, and optimising central support functions. The interview also touched on Optima’s £210 million UK Armed Forces contract, now being mobilised, and £8.3 million of new business either signed or at preferred bidder stage—positioning the company for growth into FY27 and FY28. Looking ahead, Thomas reaffirmed the company’s target of reaching £200 million in revenue and £40 million EBITDA, driven by organic growth, operational efficiency, and further M&A. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications for future updates. #OptimaHealth #HealthcareStocks #EarningsUpdate #MergersAndAcquisitions #OperationalTransformation #MentalHealthServices #HealthcareUK #RevenueGrowth #EBITDA #ProactiveInvestors

MustGrow Biologics Corp Chief Operating Officer Colin Bletsky joined Steve Darling from Proactive to announce outstanding performance results for the company’s organic TerraSante™ biofertility product, based on large-scale customer performance data from commercial potato operations in Washington State and Idaho. The results demonstrate meaningful improvements in crop yield, size, and overall quality when TerraSante™ is incorporated into existing grower production programs. Bletsky told Proactive that one Washington State farming customer recorded consistent and substantial improvements in potato yield, tuber size, and crop quality using TerraSante™ at a dose rate of 11 pounds per acre. The performance data was generated on a large commercial potato field, providing a real-world validation of the product’s effectiveness at scale. Based on the improved size, quality, and yield of the crop, the farmer estimated an approximate increase in revenue of US$5,000 per acre, achieved at a product cost of just US$180 per acre for TerraSante™. Additional work completed across potato fields in Idaho has also demonstrated significant agronomic benefits. These trials showed measurable improvements to both soil health and crop vigor when TerraSante™ was applied within growers’ existing production programs, reinforcing the product’s versatility and compatibility with established farming practices. TerraSante™ is a mustard-derived, organic biofertilizer formulated as a soluble, mixable product containing nutritious plant proteins and carbohydrates. These inputs are designed to feed both the soil and beneficial soil microbes, helping to improve soil biology, nutrient availability, and overall plant performance in a sustainable manner. The product is currently registered and approved for sale in six key U.S. agricultural states California, Florida, Arizona, Idaho, Oregon, and Washington. TerraSanteTM is also certified under the Organic Materials Review Institute (OMRI) Listed® program and California’s Organic Input Material (OIM) Program, allowing it to be used in certified organic farming operations. Bletsky noted that the strong commercial performance data further supports MustGrow’s strategy to commercialize sustainable, high-performance biological solutions that deliver both environmental benefits and compelling economic returns for growers. #proactiveinvestors #mustgrowbiologicscorp #tsxv #mgro #otcqb #mgrof #mustardseed #TerraSante #Biofertility #AgricultureTechnology #SustainableFarming #OrganicFarming #CropEnhancement #SoilHealth #AgriBusiness #ProductDistribution #florida #grapefruit #bellpeppers #watermelons #tomatos

Temas Resources CEO Tim Fernback joined Steve Darling from Proactive to provide an update on the continued advancement of the company’s La Blache Property in Quebec, along with significant progress on its proprietary metallurgical technology initiatives. Fernback outlined Temas’ unique dual-business model, explaining that the company operates both as a metallurgical technology developer and as an advancing critical minerals exploration and development company focused on titanium, vanadium, and iron. Fernback noted that Temas has completed approximately 45,000 metres of drilling at the La Blache Property to date, establishing a substantial geological database for the project. He highlighted that the company has already delivered a Preliminary Economic Assessment (PEA), which demonstrates the scale and strength of the asset. The PEA indicates approximately $6.6 billion of in-situ rock value underground with an internal rate of return (IRR) of over 60%, underscoring the project’s robust economic potential. A key component of Temas’ strategy is its proprietary regenerative chloride leach (RCL) platform technology. Fernback explained that the RCL system is designed to extract metals from complex mineralized rock while recycling reagents within a closed-loop process. By reusing key inputs, the technology is engineered to significantly reduce both operating costs and energy consumption compared to conventional processing methods. According to Fernback, the RCL platform can deliver approximately 65% savings versus traditional metallurgical approaches, positioning it as a potentially disruptive solution for the global mining and processing industry. Temas is actively evaluating international licensing and joint venture opportunities for the RCL technology, as the company looks to commercialize the platform beyond its own projects and create an additional revenue stream independent of mining operations. The interview also highlighted the company’s recently completed 2,300-metre drilling program at La Blache, with assay results expected in early 2026. Fernback added that planned work in the coming year includes advancing both the La Blache and Lac Brûlé projects toward feasibility-stage studies, while continuing to strengthen the company’s metallurgical division and expand its technology footprint. Fernback also pointed to the company’s recently completed Australian initial public offering, which successfully raised $11.00 million. He said the financing leaves Temas fully funded for its upcoming work programs, positioning the company to execute on both its project development and technology growth strategies without near-term funding constraints. #proactiveinvestors #temasresourcescorp #asx #tio #cse #tmas #otcqb #tmasf #LaBlacheProject #MiningNews #CriticalMinerals #Titanium #Vanadium #IronOre #MetallurgicalTechnology #RCLTechnology #QuebecMining #ResourceStocks #DrillingUpdate #2026Outlook

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about new clinical data from its phase two melanoma study, known as the SCOPE trial, featuring its lead ImmunoBody candidate, iSCIB1+. L’Huillier highlighted that the trial has achieved the objectives set out for it, confirming the parameters for the company’s upcoming registrational phase three study. The findings now provide clarity on dosing, patient population, and trial design. “Our SCOPE study…has met the objectives that we set out for it,” he said. A key point of the discussion focused on the data, which showed a 74% progression-free survival rate at 16 months for iSCIB1+. This compares to 46% at 12 months for the standard of care, which typically includes dual checkpoint inhibitors Ipilimumab and Nivolumab. L’Huillier noted this as a "really strong and durable benefit" on top of existing treatments. He also addressed how iSCIB1+ performed across patient subgroups where existing therapies are typically less effective—such as BRAF, PD-L1 status, and those with prior checkpoint treatment—with results showing clinically meaningful benefit across all. Scancell now plans to begin its phase three trial in late 2026, having received supportive regulatory feedback. L’Huillier also said the data has materially strengthened the company’s case for partnering and financing opportunities as part of a dual-track strategy to either partner or proceed independently. Watch the full video for more insights. Like, subscribe, and enable notifications so you never miss an update from Proactive’s YouTube channel. #Scancell #Melanoma #CancerResearch #ClinicalTrials #Immunotherapy #iSCIB1 #BiotechNews #Phase3Trial #Oncology #ProactiveInvestors